Almeda Ventures

Almeda Ventures operates from Tel Aviv, anchoring its activity in one of the world’s most active healthcare and life sciences innovation ecosystems. Israel’s combination of strong technical talent, world-class clinical research environments, and an unusual density of medical device, digital health, and biotech companies creates a distinctive context for early-stage healthcare investing, and Almeda has positioned itself to engage with founders building inside that environment.

The healthcare focus runs through digital health, biotech, and medical devices and MedTech. Within that, the firm tends to favor companies whose technologies emerge from Israeli academic, clinical, or military research environments and whose paths combine technical novelty with credible clinical or commercial applications. The portfolio orientation reflects Israel’s particular strengths in computational biology, medical imaging, and minimally invasive medical devices, and the firm engages with companies across these categories.

Check sizes run from $1M to $5M across seed, Series A, and Series B rounds. That positioning allows Almeda to be either a lead or significant participant in early institutional rounds, often partnering with other Israeli funds, US co-investors, and strategic partners as portfolio companies move toward international scaling. Founders should expect diligence that engages seriously with the underlying science and clinical questions, alongside commercial and regulatory considerations.

The team brings investing, operating, and clinical or scientific backgrounds, with relationships across Israeli research institutions, hospital systems, and the international healthcare investor community. Those relationships are a meaningful part of what the firm offers portfolio companies, particularly for those whose progression depends on access to clinical advisors, regulatory expertise, or follow-on capital from US and European investors who often participate in later Israeli healthcare rounds. The firm is comfortable working with founders whose first language is Hebrew and whose product roadmaps target international markets from inception.

For founders, working with Almeda means an investor that takes the science seriously, engages on clinical and regulatory strategy, and is willing to be patient with the development timelines that medical devices, biotech, and digital health companies require. Post-investment support tends to focus on follow-on syndication including with US and European co-investors, clinical advisor and customer introductions, and helping companies navigate the practical complexity of building globally competitive healthcare companies from an Israeli base. The firm is a less natural fit for companies whose plans do not include meaningful international ambitions or for founders who want a passive check. It is a strong fit for technically and clinically credible Israeli healthcare teams whose ambitions are global and who want an investor with the local relationships, the international network, and the patience to support a multi-year path from formation through international scaling. Almeda’s working style tends to be substantive and clinically literate.